CD81tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma
CD81tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma
复制标题
DOI：
10.1002/ijc.28581
复制
发表时间：
2014-05-15
影响因子：
6.4
通讯作者：
Tanioka, Miki
中科院分区：
文献类型：
--
作者：
Fujii, Hiroko;Arakawa, Akiko;Tanioka, Miki
据报道，肿瘤浸润淋巴细胞（TIL）是多种癌症的预后因素，并且是免疫治疗的有希望的靶标。为了研究 TIL 是否对血管肉瘤患者的预后有影响，通过免疫组织化学染色 CD4、CD8、FOXP3 和 Ki67 回顾性评估了 55 名未经治疗的血管肉瘤患者（40 例皮肤局限性肿瘤的 1 期患者、4 例淋巴结转移的 2 期患者和 11 例远处转移的 3 期患者）。 Kaplan-Meier 方法用于估计 1 期患者的总体生存率。通过对数秩检验分析生存率差异。原发肿瘤中 CD8(+) TIL 数量较多的患者与 CD8(+) TIL 数量较低的患者相比，生存时间明显更长。此外，TIL中CD8的数量与远处无转移期呈正相关。 3期远处转移患者的原发性TIL（CD4+CD8）和CD8（+）原发性TIL总数与其总生存率呈正相关。为了评估CD8(+)效应T细胞是否被激活或分化，对外周血单核细胞(PBMC)进行流式细胞术分析。血管肉瘤患者 (n=10) 的 PBMC 中产生 IFN-的 CD8(+) T 细胞的百分比不仅显着高于健康对照者 (n=20)，而且还显着高于晚期黑色素瘤患者 (n=11)。这些结果表明抗肿瘤免疫在血管肉瘤中具有临床相关性。有什么新消息？据报道，肿瘤浸润淋巴细胞（TIL）是多种癌症的预后因素。在这项研究中，作者调查了 TIL 是否对血管肉瘤的预后有影响。他们发现，较高数量的 CD8(+) TIL 与较长的无远处转移时间和较好的预后相关。 PBMC 分析显示，血管肉瘤患者的 CD8(+) 效应 T 细胞数量也高于健康对照。因此，基于 TIL 的免疫疗法可能为血管肉瘤的治疗提供一种有前景的方法。
Tumor-infiltrating lymphocytes (TILs) have been reported as a prognostic factor in various cancers and are a promising target for immunotherapy. To investigate whether TILs have any impact on the prognosis of angiosarcoma patients, 55 non-treated patients (40 patients at stage 1 with cutaneous localized tumors, 4 patients at stage 2 with lymph node metastases and 11 patients at stage 3 with distant metastases) with angiosarcoma were evaluated retrospectively by immunohistochemistry stained CD4, CD8, FOXP3 and Ki67. The Kaplan-Meier method was used to estimate overall survival with patients at stage 1. Survival differences were analyzed by the log-rank test. Patients with higher numbers of CD8(+) TILs in their primary tumors survived significantly longer compared with patients with lower values. Moreover, the number of CD8 in TILs was positively correlated with a distant metastasis-free period. The total number of primary TILs (CD4 plus CD8) and CD8(+) primary TILs of stage 3 patients with distant metastases was positively correlated with their overall survival. To evaluate whether CD8(+) effector T cells are activated or differentiated, flow cytometric analysis of peripheral blood mononuclear cells (PBMC) was performed. The percentages of CD8(+) T cells producing IFN- in PBMC were significantly higher in patients with angiosarcoma (n=10) compared not only with that of healthy controls (n=20) but also patients with advanced melanoma (n=11). These results suggest that anti-tumor immunity is clinically relevant in angiosarcoma.What's new? Tumor-infiltrating lymphocytes (TILs) have been reported to be a prognostic factor in various cancers. In this study, the authors investigated whether TILs have any impact on the prognosis of angiosarcoma. They found that higher numbers of CD8(+) TILs correlated with both a longer period free of distant metastases, and a more favourable prognosis. PBMC analysis showed that patients with angiosarcoma also had higher numbers of CD8(+) effector T cells than did healthy controls. TIL-based immunotherapy may thus provide a promising approach to the treatment of angiosarcoma.